MHC Class I Antigens In Malignant Cells / SpringerBriefs in Cancer Research Bd.1 (PDF)
Immune Escape And Response To Immunotherapy
(Sprache: Englisch)
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for...
sofort als Download lieferbar
eBook (pdf)
54.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „MHC Class I Antigens In Malignant Cells / SpringerBriefs in Cancer Research Bd.1 (PDF)“
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ¿
Autoren-Porträt von Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
Teresa Cabrera Castillo, Ph.D., MD., is a Full Professor at the Department of Biochemistry, Molecular Biology, and Immunology at the University of Granada and a Medical Immunology Specialist at Hospital Universitario Virgen de las Nieves. Natalia Aptsiauri, Ph.D., MD., is a Senior Staff Scientist at the Department of Clinical Analysis and Immunology, University Hospital Virgen de las Nieves Angel Miguel Garcia Lora, Ph.D., is a Senior Staff Scientist at the Department of Clinical Analysis and Immunology, University Hospital Virgen de las Nieves Please see attached CVs for more detail.
Bibliographische Angaben
- Autoren: Natalia Aptsiauri , Angel Miguel Garcia-Lora , Teresa Cabrera
- 2013, 2013, 51 Seiten, Englisch
- Verlag: Springer-Verlag GmbH
- ISBN-10: 1461465435
- ISBN-13: 9781461465430
- Erscheinungsdatum: 26.02.2013
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: PDF
- Größe: 3.99 MB
- Ohne Kopierschutz
- Vorlesefunktion
Sprache:
Englisch
Kommentar zu "MHC Class I Antigens In Malignant Cells / SpringerBriefs in Cancer Research Bd.1"
Schreiben Sie einen Kommentar zu "MHC Class I Antigens In Malignant Cells / SpringerBriefs in Cancer Research Bd.1".
Kommentar verfassen